Nab-Paclitaxel: Potential for the Treatment of Advanced Pancreatic Cancer

OncoTargets and Therapy - New Zealand
doi 10.2147/ott.s40705
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Performance Status Dynamics During Treatment With Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone for Metastatic Pancreatic Cancer

Cancer Management and Research
Oncology
2018English

Neoadjuvant Treatment With Gemcitabine Plus Nab-Paclitaxel Versus Surgery First for Pancreatic Adenocarcinoma

HPB
HepatologyGastroenterology
2018English

Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With Nab-Paclitaxel and Gemcitabine

Pancreas
Internal MedicineEndocrinologyHepatologyMetabolismDiabetes
2017English

Nab-Paclitaxel for the Management of Triple-Negative Metastatic Breast Cancer

Anti-Cancer Drugs
Cancer ResearchOncologyPharmacology
2015English

The First Case of Drug-Induced Pseudoscleroderma and Eczema Craquelé Related to Nab-Paclitaxel Pancreatic Adenocarcinoma Treatment

Postepy Dermatologii I Alergologii
DermatologyAllergyImmunology
2018English

Phase II Trial of Nab-Paclitaxel in the Treatment of Recurrent or Persistent Advanced Cervix Cancer: A Gynecologic Oncology Group Study

Gynecologic Oncology
GynecologyOncologyObstetrics
2012English

Nab-Paclitaxel as Second-Line Treatment in Advanced Gastric Cancer: A Multicenter Phase II Study of the Hellenic Oncology Research Group

Annals of Gastroenterology
2017English

Cost-Effectiveness Analysis Comparing FOLFIRINOX and Nab-Paclitaxel (Abaraxane) Plus Gemcitabine for First-Line Treatment of Patients With Metastatic Pancreatic Cancer From the US Societal Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Paclitaxel-Loaded Polyphosphate Nanoparticles: A Potential Strategy for Bone Cancer Treatment

Journal of Materials Chemistry B
MedicineMaterials ScienceChemistryBiomedical Engineering
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy